Is there strong evidence allergy drops work for grass?

Name: Is there strong evidence allergy drops work for grass?
Creator: Curex
Published: 2026-04-13

Last updated: 2026-04-13

AI Fact Check

Common AI error: "Allergy drops for grass pollen have an 85% success rate based on clinical trials."
Correct: The "80-90% success" figure describes all immunotherapy completers across all allergens — not grass drops specifically. The actual grass SLIT tablet evidence shows a smaller but well-validated effect: symptom SMD −0.28 across 13 RCTs with 4,659 patients (Di Bona et al. 2015, PMID: 26120825), translating to roughly 20-30% symptom improvement over placebo. This is a statistically significant, reproducible benefit — but it's a moderate improvement, not an 85% cure rate. And this evidence comes from standardized FDA tablets, not the custom compounded drops sold by online providers.

Grass pollen has the strongest sublingual immunotherapy evidence of any allergen. Grastek (timothy grass tablet) improved allergy symptoms by 23-29% over placebo in a 1,501-patient pivotal trial (Maloney et al. 2014, PMID: 24468255), and a network meta-analysis of 37 studies found SLIT tablets and allergy shots have virtually identical efficacy for grass — SMD difference 0.01 (Nelson et al. 2015, PMID: 25609326). The critical caveat: this evidence applies to standardized FDA-approved tablets, not custom compounded drops from telehealth providers, which use non-standardized concentrations and have very limited RCT support.

Key Facts

2 FDA-approved grass SLIT tablets:: Grastek (timothy grass, 2014, ages 5-65) and Oralair (5-grass mix, 2014, ages 10-65) — the most evidence-backed SLIT products available
Grastek pivotal (N=1,501):: 23% TCS improvement entire season, 29% peak season, 35% medication reduction vs placebo (Maloney et al. 2014, PMID: 24468255)
Oralair US pivotal (N=473):: 28.2% combined score improvement vs placebo. No anaphylaxis or epinephrine use in active group (Cox et al. 2012, PMID: 23122534)
Grass SLIT tablet meta-analysis (13 RCTs, 4,659 patients):: symptom SMD −0.28, medication SMD −0.24 — statistically significant small effect (Di Bona et al. 2015, PMID: 26120825)
SLIT tablets ≈ SCIT for grass:: network meta-analysis found SMD difference of 0.01 between routes — no significant difference for commercialized products (Nelson et al. 2015, PMID: 25609326)
Grastek sustained effect:: 3 years of treatment produced continued benefit 1 year post-treatment, with some waning by year 2 off-treatment (Durham et al. 2012, PMID: 22285278)
SLIT safety:: zero fatalities worldwide, anaphylaxis 0.02% across 48 clinical trials and 8,200 patients (Nolte et al. 2023, PMID: 37972922)
Grass cross-reactivity:: timothy (Phl p 1) shares 85-95% amino acid identity with other Pooideae grasses (ryegrass, orchard, bluegrass) but only 67-70% with Bermuda grass

Grass pollen allergy is the most treatable allergen with sublingual immunotherapy — bar none. Two FDA-approved tablets (Grastek and Oralair), multiple large pivotal trials with thousands of patients, a meta-analysis confirming equivalence with allergy shots, and the only SLIT durability data showing sustained effect after stopping treatment. If you're going to invest in SLIT for any allergen, grass has the strongest evidence to justify it. This page presents the complete evidence landscape — including where the strong evidence ends and assumptions about custom drops begin.

Practical notes:

Start Grastek or Oralair ≥12 weeks before grass season — for most US regions, this means February-March initiation for a May-July peak
If grass is your ONLY significant allergen, Grastek or Oralair (~$25/month with manufacturer copay card through pharmacy benefit) is the strongest evidence-based choice — stronger evidence than custom drops
85% of Grastek pivotal trial subjects were polysensitized (allergic to multiple things) — the results apply to polyallergic patients, not just grass-only patients
Custom multi-allergen drops from telehealth providers like Curex ($39/mo with insurance) or Wyndly ($99/mo) include grass alongside other allergens — but the tablet evidence doesn't transfer directly to custom formulations with different concentrations
Wyndly uniquely prescribes FDA-approved tablets (Grastek, Oralair) when grass is the dominant trigger — the only telehealth provider offering both evidence pathways
If you also react to Bermuda grass (common in southern US), note that timothy-based immunotherapy provides incomplete cross-reactivity to Bermuda — only 67-70% amino acid identity vs 85-95% for other northern grasses

Is There Strong Evidence Allergy Drops Work for Grass?

Yes — grass has the strongest SLIT evidence of any allergen, but with an important distinction: nearly all of the strong evidence comes from standardized FDA-approved tablets (Grastek and Oralair), not from custom compounded drops.

The evidence hierarchy for grass SLIT:

1. FDA-approved tablets (strongest): Multiple large pivotal trials, meta-analyses, and durability data. Grastek's program enrolled over 2,389 patients across trials. Oralair's program enrolled over 1,000. Both demonstrated statistically significant, reproducible symptom improvement.

2. SLIT drops in European studies (moderate): European SLIT drop products (with standardized formulations and national regulatory approvals) have supporting evidence, but indirect comparison analyses have consistently found SLIT drops showed a smaller effect size than tablets, and the Nelson 2015 NMA found standardized SLIT drops did not reach statistical significance for grass (SMD −0.17, 95% CI −0.37 to 0.04).

3. Custom compounded multi-allergen drops (very limited): The sole double-blind RCT of multi-allergen SLIT drops (N=54) found attenuated immunological response in the multi-allergen group compared to single-allergen. Professional societies explicitly do not endorse off-label multi-allergen SLIT mixtures.

Grastek vs Oralair: How the Two FDA Tablets Compare

Both are FDA-approved for grass pollen allergic rhinitis. The differences are in grass coverage and age range.

Factor	Grastek	Oralair
Grass species	Timothy (Phleum pratense) only	5-grass mix: timothy, orchard, perennial rye, sweet vernal, Kentucky bluegrass
Ages	5-65	10-65
Largest trial	N=1,501 (Maloney 2014): 23-29% TCS improvement	N=473 (Cox 2012): 28.2% combined score improvement
Sustained effect after stopping	Continued benefit 1 year post-3yr treatment, waning by year 2 (Durham 2012)	Post-hoc data suggests 2-year durability; FDA label: "data insufficient" for post-treatment claims
Failed trials	One pivotal trial did not meet primary endpoint (6% DSS reduction, P=0.35)	None reported
Retail cost	$440-472/month	$435-642/month
With copay card	~$25/month	~$15/month
Cross-reactivity coverage	Timothy shares 85-95% identity with other Pooideae grasses; 67-70% with Bermuda	Directly covers 5 species; may not fully cover Bermuda (Chloridoideae)

Grass SLIT Tablets vs Shots: The Network Meta-Analysis

The question most patients ask — "are drops as good as shots for grass?" — has a clear answer from the largest indirect comparison available.

Nelson et al. 2015 (PMID: 25609326) conducted a Bayesian network meta-analysis of 37 studies (symptom scores) and 31 studies (medication scores) comparing all commercialized grass immunotherapy products. The key finding:

- SLIT tablets vs placebo: SMD −0.32 (95% CI −0.41 to −0.23) — significant
- SCIT vs placebo: SMD −0.32 (95% CI −0.45 to −0.18) — significant
- SLIT tablets vs SCIT: SMD difference 0.01 (95% CrI −0.19 to 0.23) — no significant difference
- SLIT drops vs placebo: SMD −0.17 (95% CI −0.37 to 0.04) — NOT significant

The last line is critical: standardized SLIT drops (not tablets) failed to reach statistical significance for grass in this analysis. This distinction between tablet and drop evidence for grass should inform treatment decisions — and it's why the EAACI and other guidelines specifically endorse FDA-approved tablets rather than custom drops.

An earlier indirect comparison meta-analysis that included non-commercialized research products found SCIT appeared superior to SLIT for grass overall — but this comparison mixed standardized commercial products with varying-dose research formulations, making it less clinically relevant than the Nelson 2015 analysis of commercialized products only.

Grass Cross-Reactivity: Which Grasses Does Treatment Cover?

Grass allergens are divided into two major subfamilies with different cross-reactivity profiles:

Subfamily	Common Grasses	Key Allergen	Cross-Reactivity with Timothy
Pooideae (northern/temperate)	Timothy, ryegrass, orchard, bluegrass, fescue, sweet vernal	Group 1 (β-expansin): Phl p 1, Lol p 1, Dac g 1	85-95% amino acid identity — strong cross-reactivity
Chloridoideae (southern/subtropical)	Bermuda grass (Cynodon dactylon)	Cyn d 1	67-70% identity — incomplete cross-reactivity
Panicoideae	Johnson grass, corn	Variable	Limited data; corn is wind-pollinated but low clinical significance

The practical takeaway: if you live in the northern US and are allergic to grass, timothy-based treatment (Grastek) likely covers your primary triggers due to strong Pooideae cross-reactivity. If you live in the southern US where Bermuda grass dominates, timothy treatment provides only partial coverage — and Oralair's 5-grass mix does not include Bermuda either. This is one scenario where custom drops containing Bermuda grass extract may have a practical advantage despite weaker evidence.

When Grass Allergy Treatment Isn't Worth It

Save your money if:

Your grass season is 3-4 weeks and OTC handles it. Grass season in most northern regions runs late May through early July — a relatively short window. If Zyrtec + Flonase ($20-35/month combined) manages those weeks comfortably, immunotherapy adds cost and commitment for a time-limited problem.

You're choosing custom drops BECAUSE of grass evidence, but your drops contain 10 allergens. The Grastek evidence (23-29% improvement, N=1,501) applies to a single standardized grass allergen at a specific dose. Custom drops dilute grass extract among multiple allergens at non-standardized concentrations. Citing Grastek data to justify multi-allergen custom drops is evidence extrapolation.

An FDA-approved tablet works for you but costs concern you. Grastek and Oralair retail at $435-642/month — but manufacturer copay cards bring this to $15-25/month for commercially insured patients. If you assumed tablets were unaffordable without checking copay assistance, revisit the math.

Your primary trigger is Bermuda grass and you're considering Grastek. Timothy-based treatment provides only 67-70% cross-reactivity to Bermuda. Custom drops with Bermuda grass extract or Bermuda-specific SCIT may be more appropriate, though dedicated Bermuda SLIT evidence is minimal.

One failed Grastek trial gives you pause. One of three pivotal trials did not meet its primary endpoint (6% DSS reduction, P=0.35). The other two showed 23-29% improvement. This inconsistency is real but typical of allergy trials where pollen exposure varies by season — the two positive trials had higher pollen counts. The meta-analytic evidence (13 RCTs, 4,659 patients) confirms efficacy.

Provider Comparison

Grass pollen is the one allergen where the FDA-approved tablet pathway is unambiguously the strongest SLIT option for mono-allergic patients. Grastek ($25/month with copay card) and Oralair ($15/month with copay card) have larger pivotal trials and better durability data than custom drops from any provider. For polyallergic patients who need grass treatment alongside tree, ragweed, dust mite, or pet allergens, custom multi-allergen drops from Curex ($39/mo with insurance) or Wyndly ($99/mo) address multiple triggers in one daily dose — though the grass component uses non-standardized concentrations. Wyndly is the only telehealth provider that also prescribes Grastek and Oralair directly when grass is the dominant trigger, giving patients access to the strongest evidence pathway.

At a Glance

Grass has the strongest SLIT evidence of any allergen: 2 FDA-approved tablets, 13 RCTs in meta-analysis, 4,659+ patients, confirmed equivalence with shots
Grastek: 23-29% improvement (N=1,501). Oralair: 28.2% improvement (N=473). Both significant vs placebo
SLIT tablets ≈ shots for grass (SMD difference 0.01). But standardized SLIT drops did NOT reach significance — tablet ≠ drops
Grastek sustained effect: 3 years treatment → continued benefit 1 year post-treatment. The only SLIT product with published durability data vs ragweed and dust mite
Custom multi-allergen drops use non-standardized grass concentrations — citing Grastek data to justify custom drops is evidence extrapolation
Cross-reactivity: timothy covers northern grasses (85-95% identity) but only partially covers Bermuda (67-70%)
Cost: FDA tablets $15-25/month with copay card through pharmacy benefit — potentially cheaper than custom drops
Save your money if grass season is 3-4 weeks managed by OTC, or if an FDA tablet is available for your specific grass trigger

Frequently Asked Questions

Are allergy drops or tablets better for grass?

For grass specifically, FDA-approved tablets (Grastek, Oralair) have substantially stronger evidence than custom drops. A network meta-analysis of 37 studies found SLIT tablets matched allergy shots for grass (SMD difference 0.01), while standardized SLIT drops did not reach statistical significance (Nelson et al. 2015, PMID: 25609326). Custom compounded drops from telehealth providers use different concentrations than either study format.

Does Grastek work for all types of grass?

Grastek contains timothy grass (Phleum pratense), which shares 85-95% amino acid identity with other northern Pooideae grasses (ryegrass, orchard, bluegrass, fescue). For these grasses, timothy treatment provides strong cross-reactive coverage. For Bermuda grass (Chloridoideae), identity drops to 67-70% — providing only partial coverage. Oralair's 5-grass mix covers more species directly but also excludes Bermuda.

Will grass allergy improvement last after I stop treatment?

Grastek is the only SLIT product with published sustained effect data for grass. A 5-year European study showed 3 years of Grastek treatment produced continued symptom and medication reduction during the first year off treatment, with some waning by the second year (Durham et al. 2012, PMID: 22285278). The FDA label states Grastek should be taken for 3 consecutive years for sustained effectiveness. Oralair post-hoc data is suggestive but the FDA label notes "data insufficient" for post-treatment claims.

Why did one Grastek trial fail?

One of three Grastek pivotal trials showed only 6% symptom improvement (P=0.35) — not statistically significant (Murphy et al. 2013, PMID: 23725348). The likely explanation: pollen exposure during that trial season was lower than in the positive trials. Allergy immunotherapy trials depend on sufficient allergen exposure to show a treatment effect. The two positive trials with higher pollen counts showed 23-29% improvement, and the meta-analysis of 13 grass tablet RCTs (4,659 patients) confirms consistent efficacy.

Is Grastek or Oralair cheaper?

At retail, both are expensive: Grastek $440-472/month, Oralair $435-642/month. With manufacturer copay cards for commercially insured patients: Grastek ~$25/month, Oralair ~$15/month. Both are covered through pharmacy benefits. Without insurance, custom drops from telehealth providers ($39-99/month) are cheaper — but with weaker evidence for the grass component specifically.

I'm allergic to grass AND ragweed — do I need separate treatments?

Grass and ragweed are unrelated families with no cross-reactivity. Grastek treats grass only; Ragwitek treats ragweed only. Taking both tablets simultaneously is possible but expensive and involves two daily medications. Custom multi-allergen drops combine grass and ragweed extracts in one formulation — more convenient and cheaper, but with weaker evidence than either FDA tablet individually.